Showing results (51-60 of 204) with videos related to
Sort By:
Pageof 21
American Journal of Hematology|April 29, 2016
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United StatesChadi Nabhan, Xiaolei Zhou, Bann-Mo Day, et al.Bone Marrow Transplantation|July 7, 2015
Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab eraAlberto Mussetti, Sean M Devlin, Hugo R Castro-Malaspina, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2012
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare StudyJonathan W Friedberg, Michelle Byrtek, Brian K Link, et al.Cancers|January 28, 2026
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) TrialErel Joffe, Anita Kumar, Joseph M Tuscano, et al.Blood|December 1, 2005
Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomasWeiyi Chen, Jane Houldsworth, Adam B Olshen, et al.Leukemia & Lymphoma|July 16, 2020
Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphomaJacob D Soumerai, Andy Ni, Anna Alperovich, et al.British Journal of Haematology|August 24, 2005
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999Paul A Hamlin, Carol S Portlock, David J Straus, et al.Blood|March 12, 2015
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphomaCraig S Sauter, Matthew J Matasar, Jessica Meikle, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 7, 2003
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-responseGeorge Sgouros, Shannon Squeri, Ase M Ballangrud, et al.Applied Immunohistochemistry & Molecular Morphology : AIMM|November 24, 2004
Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphomaQianxun Xiao, Ning Shen, Cyrus V Hedvat, et al.Pageof 21